Medichem Welcomes Pablo Álvarez as New CEO


(Barcelona, April 10) Medichem, a trusted business partner in the pharmaceutical industry, is pleased to announce the appointment of Pablo Álvarez as its new Chief Executive Officer (CEO), effective April 8, 2024. With an excellent track record in the pharmaceutical industry and a commitment to lead Medichem into a new phase of growth and success.

Pablo Álvarez joins Medichem with extensive international experience across Europe, the United States, Latin America, and China. His career highlights include key roles at leading pharmaceutical companies such as Almirall, AstraZeneca, BMS, GSK, and McKinsey. Notably, he brings nearly a decade of successful leadership in the U.S. market, demonstrating a strong track record in overcoming complex challenges and driving growth strategies.

Pablo holds a PharmD, a PhD Summa Cum Laude, and postdoctoral experience from MIT (Massachusetts Institute of Technology), complemented by business management studies at IESE Business School in Barcelona. His strategic vision and commitment to excellence align seamlessly with Medichem’s mission to deliver solutions globally.

“I am excited to join Medichem and build upon its rich legacy,” Pablo Álvarez commented. “We have a bright future ahead, with a solid core business that enables strategic investments, such as the development of an injectable plant in Asturias. I look forward to collaborating with the talented team at Medichem to drive continued success and innovation in the pharmaceutical sector.”

Pablo Álvarez’s appointment marks an important milestone for Medichem as it continues its commitment to excellence and delivering value to its business partners in the pharmaceutical industry.